Abstract:The frequency and poor prognosis of patients with metastatic colorectal cancer (mCRC) emphasizes the requirement for improved biomarkers for use in the treatment and prognosis of mCRC. In the present study, somatic variants in exonic regions of key cancer genes were identified in mCRC patients. Formalin-fixed, paraffin-embedded tissues obtained by biopsy of the metastases of mCRC patients were collected, and the DNA was extracted and sequenced using the Ion Torrent Personal Genome Machine. For the targeted amplification of known cancer genes, the Ion AmpliSeq (TM) Cancer Panel, which is designed to detect 739 Catalogue of Somatic Mutations in Cancer (COSMIC) mutations in 604 loci from 46 oncogenes and tumor suppressor genes using as little as 10 ng of input DNA, was used. The sequencing results were then analyzed using the Ampliseq (TM) Variant Caller plug-in within the Ion Torrent Suite software. In addition, Ingenuity Pathway software was used to perform a pathway analysis. The Cox regression analysis was also conducted to investigate the potential correlation between alteration numbers and clinical factors, including response rate, disease-free survival and overall survival. Among 10 specimens, 65 genetic alterations were identified in 24 genes following the exclusion of germline mutations using the SNP database, whereby 41% of the alterations were also present in the COSMIC database. No clinical factors were found to significantly correlate with the alteration numbers in the patients by statistical analysis. However, pathway analysis identified 'colorectal cancer metastasis signaling' as the most commonly mutated canonical pathway. This analysis further revealed mutated genes in the Wnt, phosphoinositide 3-kinase (PI3K)/AKT and transforming growth factor (TGF)-beta/SMAD signaling pathways. Notably, 11 genes, including the expected APC, BRAF, KRAS, PIK3CA and TP53 genes, were mutated in at least two samples. Notably, 90% (9/10) of mCRC patients harbored at least one 'druggable' alteration (range, 1-6 alterations) that has been linked to a clinical treatment option or is currently being investigated in clinical trials of novel targeted therapies. These results indicated that DNA sequencing of key oncogenes and tumor suppressors enables the identification of 'druggable' alterations for individual colorectal cancer patients.

Mtctscan: a Comprehensive Platform for Annotation and Prioritization of Mutations Affecting Drug Sensitivity in Cancers

PTMsnp: A Web Server for the Identification of Driver Mutations That Affect Protein Post-translational Modification

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Tsnad: an Integrated Software for Cancer Somatic Mutation and Tumour-Specific Neoantigen Detection

"Druggable" Alterations Detected by Ion Torrent in Metastasis Colorectal Cancer Patients

scTML: a pan-cancer single-cell landscape of multiple mutation types

The signature of pharmaceutical sensitivity based on ctDNA mutation in eleven cancers.

CPADS: a Web Tool for Comprehensive Pancancer Analysis of Drug Sensitivity.

CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response

Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population

OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis

Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis.

Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

A Comprehensive Tool for Tumor Precision Medicine with Pharmaco-Omics Data Analysis

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation

'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients.

CMTTdb: the Cancer Molecular Targeted Therapy Database

Systematic identification of genomic markers of drug sensitivity in cancer cells

Representing mutations for predicting cancer drug response